İsmail Beypınar, Eskişehir City Hospital, Department of Medical Oncology, Eskişehir, Turkey
Fuzuli Tuğrul, Eskişehir City Hospital, Department of Radiation Oncology, Eskişehir, Turkey
Introduction: The utility of the inflammatory markers on definitive chemoradiation is worked on multiple cancers. Several studies had shown that tumor progression and prognosis were associated with immune status and nutritional condition. In this study, we aimed to elucidate the relationship between inflammatory markers and chemoradiation response in multiple cancer types in terms of tumor volume.
Methods: The patients who had been diagnosed with cancer and treated with concurrent chemotherapy and radiotherapy were included in the study. The patient characteristics, lymphocyte-neutrophil counts, hemoglobin, albumin and C-reactive protein levels, pathologic tumor subtype, stage of the disease, treatment modalities, tumor volumes, chemotherapeutic agents, and chemoradiotherapy outcome after the treatment were recorded.
Results: A total of 85 patients were enrolled in the study. The most frequent diagnoses were brain and rectal cancers following lung carcinomas. The most commonly used concurrent chemotherapy protocol was capecitabine. Sixty-seven percent of the patients have partial remission after chemoradiation, and 24.7% had complete remission. No correlations were observed between the volume reduction and inflammatory indexes. Also, the median alteration in tumor volume was not different between neutrophil to lymphocyte ratio (NLR) – prognostic nutritional index (PNI) high and low groups.
Conclusion: In this study, we found no relationship between tumor volume alteration and inflammatory markers. Although there was no association with the tumor volume change, NLR was a prognostic marker in patients who underwent definitive chemoradiation.
Key words: Cancer, Prognostic Nutritional Index, Neutrophil Lymphocyte Ratio, Prognosis, Chemoradiation
Eskisehir Med J. Ahead of print.